Quantcast
Last updated on April 19, 2014 at 7:22 EDT

Phase III Results Show Mirabegron Improves Key OAB Symptoms

March 22, 2011

TOKYO, March 22, 2011 /PRNewswire-FirstCall/ — Astellas Pharma
Inc.(TSE:4503,”Astellas”) ( http://www.astellas.com/en/corporate/) today
announced the results of two pivotal phase III clinical trials for
mirabegron, the first of a new class of compounds under development for the
treatment of overactive bladder (OAB), show mirabegron significantly improves
key OAB symptoms – urinary incontinence and frequency of micturition[1,2].
These data were presented for the first time this week at the 26th annual
congress of the European Association of Urology, in Vienna, Austria, 18-22
March 2011
.

After 12 weeks treatment with once daily mirabegron, significant
improvements from baseline were seen in the co-primary endpoints,
incontinence episodes/24 hours and micturitions/24 hours, compared with
placebo (p<0.05)[1,2]. Significant improvements were also recorded in the key
secondary endpoints – incontinence episodes/24 hours and micturitions/24
hours at week 4 of treatment (p<0.05 vs placebo), and volume of urine
voided/micturition at the final visit (p<0.05 vs placebo)[1,2]. In both
studies, mirabegron was well tolerated with low levels of adverse events[1,2].

“The findings of these studies are very exciting. Mirabegron would
represent the first oral OAB drug treatment with a completely new mode of
action since the launch of oxybutynin several decades ago, and, if approved,
would represent the first beta-3 adrenoceptoragonist to ever come to the
market. Unlike antimuscarinics, mirabegron works by improving the storage
capacity of the bladder. As these two studies suggest mirabegron has the
potential to provide an effective new treatment option for OAB patients who
continue to suffer from the distressing symptoms of incontinence and frequent
need to pass urine” said Mr. VikKhullar, from St. Mary’s Hospital, Imperial
College, London, and principal investigator of the European-Australian Phase
III trial.

Mirabegron is a potent and selective beta-3 adrenoceptor (beta3-AR)
agonist which activates beta3-ARs on the detrusor muscle of the bladder to
facilitate filling of the bladder and storage of urine[3,4]. It is being
developed by Astellas whose global drug, Vesicare(R) (solifenacin) is
currently one of the most widely used treatments for OAB[5].

“Vesicarehas brought health benefits to people with OAB around the world
since it was first launched in 2004, while mirabegron, with its different
mode of action, complements Vesicare and is an important addition to our
urology portfolio,” said Masafumi Nogimori, President and Chief Executive
Officer of Astellas Pharma Inc.

The new Phase III data confirm and support findings from smaller Phase
II, dose-finding studies in which significant improvements were seen in a
broad range of OAB symptoms, including incontinence episodes and micturition
frequency[6,7].

“By improving symptoms through its action on beta-3 receptors, mirabegron
offers an entirely different approach to existing OAB management which may
provide good news for the many patients who are unable to achieve the right
balance of efficacy and tolerability from current available treatments for
OAB,” said Dr. Victor Nitti, from NYU Langone Medical Center, New York, USA,
and principal investigator of the North American Phase III trial.

Astellas submitted a market authorization application for mirabegronin
Japan in June 2010and expects the submission to FDA and EMA in 2Q fiscal year
2011(July to September, 2011).

About Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a global pharmaceutical
company dedicated to improving the health of people around the world through
the provision of innovative and reliable pharmaceutical products. Astellas
has approximately 16,000 employees worldwide. The organization is committed
to becoming a global category leader in urology, immunology and infectious
diseases, neuroscience, DM complications and metabolic diseases and oncology.
For more information on Astellas Pharma Inc., please visit our website at
http://www.astellas.com/en.

About VESIcare

INDICATION AND DOSAGE

VESIcare tablets are indicated for the treatment of overactive bladder
with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The recommended dose of VESIcare is 5 mg once daily. If the 5-mg dose is well
tolerated, the dose may be increased to 10 mg once daily.

IMPORTANT SAFETY INFORMATION

VESIcare is contraindicated in patients with urinary retention, gastric
retention, uncontrolled narrow-angle glaucoma, and in patients with
hypersensitivity to the product.

Angioedema of the face, lips, tongue and/or larynx have been reported
with VESIcare. In some cases angioedema occurred after the first dose.
Angioedema associated with upper airway swelling may be life threatening. If
involvement of the tongue, hypopharynx, or larynx occurs, VESIcare should be
promptly discontinued and appropriate therapy and/or measures necessary to
ensure a patent airway should be promptly provided.

VESIcare should be administered with caution to patients with bladder
outflow obstruction, decreased gastrointestinal motility, controlled
narrow-angle glaucoma, or reduced renal or hepatic function. Doses of
VESIcare higher than 5 mg are not recommended in patients with severe renal
impairment, moderate hepatic impairment, or when administered with
ketoconazole or other potent CYP3A4 inhibitors. Use of VESIcare in patients
with severe hepatic impairment is not recommended.

In placebo-controlled studies, the most common adverse events reported by
patients were dry mouth (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%,
2.9%),blurred vision (3.8%, 4.8%, 1.8%), and dyspepsia (1.4%, 3.9%, 1.0%)
with VESIcare 5 mg, 10 mg, and placebo, respectively.

The overall rate of serious adverse events was 2%. For the 10-mg dose,
three intestinal serious adverse events were reported (one fecal impaction,
one colonic obstruction, and one intestinal obstruction). For the 5-mg dose,
one case of angioneurotic edema was reported.

For more information, please on VESIcare, please visit our website at:
http://www.astellas.us/docs/vesicare.pdf

References

1) Khullar V, Cambronero J, Stroberg P, Angulo J, Boerrigter P, Blauwet
MB, Wooning M The efficacy and tolerability of mirabegron in patients with
overactive bladder – results from a European-Australian Phase III trial.
Presented at the 26th Annual Congress of the European Association of Urology,
Vienna, Austria, 18-22 March 2011.

2) Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N. The
efficacy and safety of mirabegron in patients with overactive bladder
syndrome – results from a North-American Phase III trial. Presented at the
26th Annual Congress of the European Association of Urology, Vienna, Austria,
18-22 March 2011.

3) Tyagi P, Tyagi V. Mirabegron, a beta3-adrenoceptor agonist for the
potential treatment of urinary frequency, urinary incontinence or urgency
associated with overactive bladder. IDrugs 2010: 13: 713-722

4) Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder.
NeurourolUrodyn. 2007;26(6):752-6.

5) IMS February 2011

6) Chapple C.R., Yamaguchi O., Ridder A et al. Clinical proof of concept
study (BLOSSOM) shows novel beta3-adrenoceptor agonist YM178 is effective and
well tolerated in the treatment of symptoms of overactive bladder.
EurUrolSuppl 2008; 7(3): 239

7) Chapple C, Wyndaele JJ, Van Kerrebroeck P et al. Dose-ranging study of
once-daily mirabegron (YM178), a novel selective beta3-adrenoceptor agonist,
in patients with overactive bladder (OAB). EurUrolSuppl 2010; 9(2): 249.

    Contacts for inquiries or additional information
    Astellas Pharma Inc. (Japan)
    Corporate Communications
    Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com/en

    Astellas Pharma US, Inc. (US)
    Jenny Keeney
    Tel: +1-847-317-5405

http://www.astellas.us

    Astellas Pharma Europe Limited (EU)
    Mindy Dooa
    Tel: +44(0)1784-419-408

http://www.astellas-europe.co.uk

SOURCE Astellas Pharma Inc.


Source: newswire